nChroma Bio has significantly reduced its workforce by half, impacting its employees and halting a crucial clinical trial. The company was investigating a potential functional cure for chronic hepatitis B virus (HBV) infection with its lead asset, CRMA-1001. Enrollment in the phase 1/2 study has been stopped as nChroma evaluates strategic alternatives for its programs. Remaining staff will now focus on the company's next-generation preclinical hepatitis B program. This restructuring follows a previous round of layoffs within the last year.
Boston, MA
https://www.fiercebiotech.com/biotech/nchroma-halves-headcount-calls-time-trial-potential-hbv-cure